Therapeutics Areas
Learner Specialties
Expires After
Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients
Treatment for R/R MCL is complicated, as the disease typically presents in elderly, unfit patients; however, emerging targeted therapy options have shown great promise based on excellent results in clinical trials. In this activity, a taped version of the live symposium at the 17th Annual International Conference on Malignant Lymphoma, expert faculty present therapeutic options, established by evidence-based practice guidelines, for patients with R/R MCL. Symposium learners voted on patient demographics and parameters such as treatment, dosing frequency, and adverse events. The experts crafted their lecture to follow thheir suggestions allowing the case studies to reflect the patients the learners see. The activity concludes with a discussion on engagement between healthcare providers and patients to improve clinical outcomes.
Episode 2 of 4 - Biomarker Testing: Shaping Personalized Medicine
For non-small cell lung cancer (NSCLC), the rates of 5-year survival have improved significantly over the past 10 years with improved early detection methods and the approval of highly effective targeted therapies. With an expansion of the treatment arsenal, it is up to clinicians to decipher the latest guideline recommendations and apply evolving clinical evidence to ensure optimal treatment selection and patient education. Join us for the second episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care in which our expert faculty explore the implications of test results for prognosis and discuss methods to empower patients to engage in their care.
Setting Up Patients for HCT and Cell Therapy Success
This self-guided course provides practical recommendations and guidance on what hematology/oncology practices can do to improve patient experience and outcomes before their patient reaches a transplant center for consultation for Hematopoietic Cell Transplantation (HCT).
Build Your Own Case Study | Obesity: Treating the Whole Patient
Obesity is a chronic, progressive, relapsing disease that impacts health and quality of life. In individuals with obesity, there are many contributors to its development and persistence, including lifestyle, social, and economic factors. If left untreated, obesity can be a primary driver of serious health consequences. By treating obesity first, complications arising from obesity may improve or resolve. Given the severity of the disease, there is a need for clinicians in primary and specialty care settings to diagnose and treat obesity so that patients can receive the most appropriate treatment and care. Evidence-based treatment options, including anti-obesity medications, are emerging for adults and children. In this immersive virtual Build Your Own Case Study | Obesity: Treating the Whole Patient, navigate through your toughest clinical challenges while leading experts reinforce essential topics, such as: Medical consequences and comorbidities of obesity Application of adiposity measures, including BMI and waist circumference Latest clinical evidence of new and emerging anti-obesity medications Best practices in shared decision-making and starting the conversation with your patients
Dermatology Dialogues | Gaining and Maintaining Flare Control in Moderate-to-Severe Atopic Dermatitis: Enhancing Patient Quality of Life
This 4 part-15 minute segmented vodcast/podcast will unite dermatology and allergy clinicians, who provide care for patients with moderate-to-severe atopic dermatitis (M-S AD).
Episode 3 of 4 - Novel Therapeutics: Changing the Treatment Landscape for NSCLC
Targeted therapies have revolutionized the treatment of non-small cell lung cancer (NSCLC) with actionable genetic alterations. However, the constantly changing treatment landscape plus the rapidly evolving clinical evidence and guidelines present challenges for busy oncology nursing teams. Tune into the third episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care to learn from about new and emerging targeted therapies for NSCLC and best practices for managing patients with acquired resistance.
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - The Interconnection of OSA and Disease-related Complications
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape.
The Evolution of HCT, Part 2: Eligibility
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 2 in a 5-part series, covering advances that have expanded eligibility for HCT and considerations for who is a candidate.
The Evolution of HCT, Part 3: Donor Availability
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
The Evolution of HCT, Part 5: Shared Care
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 5 in a 5-part series, exploring how shared and coordinated care between transplant centers and hematology/oncology practices can help overcome barriers to HCT and improve patient outcomes and experience.
Build Your Own Case Study | From Evidence to Practice: Enhancing T2D Outcomes with Informed Approaches on Obesity
The tie between type 2 diabetes (T2D) and overweight/obesity is a significant global public health issue, supported by decades of extensive research. Despite formal clinical guidelines recommendations in addressing both diseases, the initiation or intensification of therapies that improve glycemic control and achieve weight reduction targets are slowly adopted into clinical practice, particularly for patients with T2D. Given the overlap of these two conditions, it is imperative that healthcare providers worldwide align clinical practice with evidence-based guidelines and the latest clinical findings using newer agents to treat both diseases.
Episode 1 of 4 - The Evolution of Biomarker Testing: Revolutionizing Treatment of NSCLC
Biomarker testing can have a significant impact on the treatment plan of patients with non-small cell lung cancer (NSCLC).  In this first episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care, expert faculty apply the latest clinical guidelines and give practical tips on breaking down barriers for oncology teams to successfully implement biomarker testing for NSCLC patients, including those in underserved populations.
Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches
New and emerging advancements in the treatment of follicular lymphoma (FL) are on the horizon. Are you and your clinical teams up for the challenge of testing your skill in applying the latest clinical evidence to these groundbreaking therapies? This independent satellite symposium is an engaging learning experience, where you’ll have the chance to compete against your colleagues in complex clinical cases of follicular lymphoma.
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies / Activity 1
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in metastatic NSCLC (mNSCLC) and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 2 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice to apply the evidence to real-world patient cases!
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment
In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will: Review guideline recommendations for biomarker testing and treatment selection Present clinical evidence for the use of current and emerging targeted therapies Discuss health disparities in biomarker testing
DIABESITY DIALOGUES: Patient Perspectives for PCPs - Tackling the Treatment Paradigms of Obesity, T2D, and Other Metabolic Disorders
There is an urgent need for effective intervention by healthcare professionals (HCPs) to address the twin epidemics of Type 2 diabetes (T2D) and obesity. Tune into the Diabesity Dialogues vodcast, where renowned physicians, Dr. Robert Kushner, MD, and Dr. Jamy Ard, MD, provide valuable insights on treatment initiation, intensification, and the effective management of diabesity in the presence of other comorbidities. Hear how our esteemed hosts harness the power of social media and discuss the latest information on GLP-1 receptor agonists (RA) and dual GIP/GLP-1 RAs and dispel potential misinformation. In this special feature, tune into patient voices from social media and learn practical tips to enhance patient-centered care and be at the forefront of transformative practices. Don’t miss this opportunity to join this cutting-edge conversation.
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
Bridging the Gap to Reach Treatment Goals in DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment. Join us for this educational Med Table Talk® LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers. This taped satellite symposium was derived from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR® on February 18, 2023.
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part II: Treating Acquired Resistance and Evaluating Next-generation Therapies
The evolution of the non-small cell lung cancer (NSCLC) treatment landscape and the discovery of predictive biomarkers that can be targeted by novel therapies or combinations is facilitating more individualized treatment. However, drug resistance plays a major role in therapeutic failure and clinicians must stay alert to the current and emerging treatment options to provide optimal care. Are you ready to test your skills amongst your colleagues? Join us for Part 2 of this question and answer based educational activity Treating Acquired Resistance and Evaluating Next-generation Therapies where our oncology experts will: Discuss treatment selection for patients with acquired resistance to targeted therapy Present the latest clinical evidence on new and emerging targeted therapies Provide strategies to promote patient engagement in their care
Episode 4 of 4 - Practical Strategies for Preventing and Mitigating Toxicities of Targeted Therapy
Despite advances with targeted therapies, adverse events (AEs) must be identified and managed for optimal treatment response, clinical outcomes, and quality of life for patients with non-small cell lung cancer (NSCLC). Join us for the final episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care, in which our expert faculty have a candid conversation about mitigating common AEs associated with targeted therapies and provide strategies for engaging underserved patients in the prevention and monitoring of these potential toxicities.
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!
The Evolution of HCT, Part 4: Addressing Barriers
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 4 in a 5-part series, examining major barriers to HCT and ways to overcome them.
Time Well Spent: Treating Obesity and Diabetes
Community Collective: Time Well Spent – Navigating the Challenges of Treating Obesity and Diabetes is an educational curriculum designed for rural primary care clinicians to enhance outcomes for individuals with obesity through improved diagnosis and use of therapy options to treat type 2 diabetes (T2D).
The Evolution of HCT, Part 1: Basics and Outcomes
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 1 in a 5-part series, including the series introduction, basics of HCT, and major advances in HCT outcomes over time.
Scroll to Top